NSAID use and clinical outcomes in COVID-19 patients : A 38-center retrospective cohort study
BACKGROUND: Non-steroidal anti-inflammatory drugs (NSAIDs) are commonly used to reduce pain, fever, and inflammation but have been associated with complications in community-acquired pneumonia. Observations shortly after the start of the COVID-19 pandemic in 2020 suggested that ibuprofen was associated with an increased risk of adverse events in COVID-19 patients, but subsequent observational studies failed to demonstrate increased risk and in one case showed reduced risk associated with NSAID use.
METHODS: A 38-center retrospective cohort study was performed that leveraged the harmonized, high-granularity electronic health record data of the National COVID Cohort Collaborative. A propensity-matched cohort of COVID-19 inpatients was constructed by matching cases (treated with NSAIDs) and controls (not treated) from 857,061 patients with COVID-19. The primary outcome of interest was COVID-19 severity in hospitalized patients, which was classified as: moderate, severe, or mortality/hospice. Secondary outcomes were acute kidney injury (AKI), extracorporeal membrane oxygenation (ECMO), invasive ventilation, and all-cause mortality at any time following COVID-19 diagnosis.
RESULTS: Logistic regression showed that NSAID use was not associated with increased COVID-19 severity (OR: 0.57 95% CI: 0.53-0.61). Analysis of secondary outcomes using logistic regression showed that NSAID use was not associated with increased risk of all-cause mortality (OR 0.51 95% CI: 0.47-0.56), invasive ventilation (OR: 0.59 95% CI: 0.55-0.64), AKI (OR: 0.67 95% CI: 0.63-0.72), or ECMO (OR: 0.51 95% CI: 0.36-0.7). In contrast, the odds ratios indicate reduced risk of these outcomes, but our quantitative bias analysis showed E-values of between 1.9 and 3.3 for these associations, indicating that comparatively weak or moderate confounder associations could explain away the observed associations.
CONCLUSIONS: Study interpretation is limited by the observational design. Recording of NSAID use may have been incomplete. Our study demonstrates that NSAID use is not associated with increased COVID-19 severity, all-cause mortality, invasive ventilation, AKI, or ECMO in COVID-19 inpatients. A conservative interpretation in light of the quantitative bias analysis is that there is no evidence that NSAID use is associated with risk of increased severity or the other measured outcomes. Our findings are the largest EHR-based analysis of the effect of NSAIDs on outcome in COVID-19 patients to date. Our results confirm and extend analogous findings in previous observational studies using a large cohort of patients drawn from 38 centers in a nationally representative multicenter database.
| Errataetall: | |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2021 |
|---|---|
| Enthalten in: |
medRxiv : the preprint server for health sciences - (2021) vom: 22. Dez. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Reese, Justin T [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
COVID-19 |
|---|
| Anmerkungen: |
Date Revised 11.02.2024 published: Electronic UpdateIn: Virol J. 2022 May 15;19(1):84. - PMID 35570298 Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1101/2021.04.13.21255438 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM32461151X |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM32461151X | ||
| 003 | DE-627 | ||
| 005 | 20240211231845.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1101/2021.04.13.21255438 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1288.xml |
| 035 | |a (DE-627)NLM32461151X | ||
| 035 | |a (NLM)33907758 | ||
| 035 | |a (PII)2021.04.13.21255438 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Reese, Justin T |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a NSAID use and clinical outcomes in COVID-19 patients |b A 38-center retrospective cohort study |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 11.02.2024 | ||
| 500 | |a published: Electronic | ||
| 500 | |a UpdateIn: Virol J. 2022 May 15;19(1):84. - PMID 35570298 | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a BACKGROUND: Non-steroidal anti-inflammatory drugs (NSAIDs) are commonly used to reduce pain, fever, and inflammation but have been associated with complications in community-acquired pneumonia. Observations shortly after the start of the COVID-19 pandemic in 2020 suggested that ibuprofen was associated with an increased risk of adverse events in COVID-19 patients, but subsequent observational studies failed to demonstrate increased risk and in one case showed reduced risk associated with NSAID use | ||
| 520 | |a METHODS: A 38-center retrospective cohort study was performed that leveraged the harmonized, high-granularity electronic health record data of the National COVID Cohort Collaborative. A propensity-matched cohort of COVID-19 inpatients was constructed by matching cases (treated with NSAIDs) and controls (not treated) from 857,061 patients with COVID-19. The primary outcome of interest was COVID-19 severity in hospitalized patients, which was classified as: moderate, severe, or mortality/hospice. Secondary outcomes were acute kidney injury (AKI), extracorporeal membrane oxygenation (ECMO), invasive ventilation, and all-cause mortality at any time following COVID-19 diagnosis | ||
| 520 | |a RESULTS: Logistic regression showed that NSAID use was not associated with increased COVID-19 severity (OR: 0.57 95% CI: 0.53-0.61). Analysis of secondary outcomes using logistic regression showed that NSAID use was not associated with increased risk of all-cause mortality (OR 0.51 95% CI: 0.47-0.56), invasive ventilation (OR: 0.59 95% CI: 0.55-0.64), AKI (OR: 0.67 95% CI: 0.63-0.72), or ECMO (OR: 0.51 95% CI: 0.36-0.7). In contrast, the odds ratios indicate reduced risk of these outcomes, but our quantitative bias analysis showed E-values of between 1.9 and 3.3 for these associations, indicating that comparatively weak or moderate confounder associations could explain away the observed associations | ||
| 520 | |a CONCLUSIONS: Study interpretation is limited by the observational design. Recording of NSAID use may have been incomplete. Our study demonstrates that NSAID use is not associated with increased COVID-19 severity, all-cause mortality, invasive ventilation, AKI, or ECMO in COVID-19 inpatients. A conservative interpretation in light of the quantitative bias analysis is that there is no evidence that NSAID use is associated with risk of increased severity or the other measured outcomes. Our findings are the largest EHR-based analysis of the effect of NSAIDs on outcome in COVID-19 patients to date. Our results confirm and extend analogous findings in previous observational studies using a large cohort of patients drawn from 38 centers in a nationally representative multicenter database | ||
| 650 | 4 | |a Preprint | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a NSAIDs | |
| 650 | 4 | |a cyclooxygenase inhibitors | |
| 650 | 4 | |a observational study | |
| 700 | 1 | |a Coleman, Ben |e verfasserin |4 aut | |
| 700 | 1 | |a Chan, Lauren |e verfasserin |4 aut | |
| 700 | 1 | |a Blau, Hannah |e verfasserin |4 aut | |
| 700 | 1 | |a Callahan, Tiffany J |e verfasserin |4 aut | |
| 700 | 1 | |a Cappelletti, Luca |e verfasserin |4 aut | |
| 700 | 1 | |a Fontana, Tommaso |e verfasserin |4 aut | |
| 700 | 1 | |a Bradwell, Katie Rebecca |e verfasserin |4 aut | |
| 700 | 1 | |a Harris, Nomi L |e verfasserin |4 aut | |
| 700 | 1 | |a Casiraghi, Elena |e verfasserin |4 aut | |
| 700 | 1 | |a Valentini, Giorgio |e verfasserin |4 aut | |
| 700 | 1 | |a Karlebach, Guy |e verfasserin |4 aut | |
| 700 | 1 | |a Deer, Rachel |e verfasserin |4 aut | |
| 700 | 1 | |a McMurry, Julie A |e verfasserin |4 aut | |
| 700 | 1 | |a Haendel, Melissa A |e verfasserin |4 aut | |
| 700 | 1 | |a Chute, Christopher G |e verfasserin |4 aut | |
| 700 | 1 | |a Pfaff, Emily |e verfasserin |4 aut | |
| 700 | 1 | |a Moffitt, Richard |e verfasserin |4 aut | |
| 700 | 1 | |a Spratt, Heidi |e verfasserin |4 aut | |
| 700 | 1 | |a Singh, Jasvinder |e verfasserin |4 aut | |
| 700 | 1 | |a Mungall, Christopher J |e verfasserin |4 aut | |
| 700 | 1 | |a Williams, Andrew E |e verfasserin |4 aut | |
| 700 | 1 | |a Robinson, Peter N |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t medRxiv : the preprint server for health sciences |d 2020 |g (2021) vom: 22. Dez. |w (DE-627)NLM310900166 |7 nnns |
| 773 | 1 | 8 | |g year:2021 |g day:22 |g month:12 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1101/2021.04.13.21255438 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2021 |b 22 |c 12 | ||